Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 159, Issue 2, 2011, Pages 394-398

  Hashimoto, Kenji ^a   Yonemori, Kan ^a   Katsumata, Noriyuki ^a   Hirakawa, Akihiro ^b   Hirata, Taizo ^a   Yamamoto, Harukaze ^a   Shimizu, Chikako ^a   Tamura, Kenji ^a   Ando, Masashi ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Biomarker; Chemotherapy; Response; Squamous cell carcinoma antigen; Uterine cervical carcinoma

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; IRINOTECAN; MITOMYCIN C; PACLITAXEL; SQUAMOUS CELL CARCINOMA ANTIGEN; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; METASTATIC CERVICAL CARCINOMA; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; WORLD HEALTH ORGANIZATION;

EID: 82255162873     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2011.07.001     Document Type: Article

References (16)

1. G. Crombach, A. Scharl, M. Vierbuchen, H. Wurz, and A. Bolte Detection of squamous cell carcinoma antigen in normal squamous epithelia and in squamous cell carcinomas of the uterine cervix Cancer 63 1989 1337 1342
2. J.M. Duk, K.H. Groenier, and H.W. de Bruijn Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma J Clin Oncol 14 1996 111 118
3. G. Scambia, P. Benedetti Panici, and E. Foti Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer J Clin Oncol 12 1994 2309 2316
4. A. Gadducci, R. Tana, S. Cosio, and A.R. Genazzani The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature Crit Rev Oncol Hematol 66 2008 10 20
5. World Health Organization. WHO handbook for reporting result of cancer treatment. Offset publication 48. Geneva: World Health Organization; 1979.
6. International Agency for Research on Cancer. WHO Chron 1969;23:323-6.
7. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
8. H.Y. Ngan, L.C. Wong, S.Y. Chan, and H.K. Ma Use of serum squamous cell carcinoma antigen assays in chemotherapy treatment of cervical cancer Gynecol Oncol 35 1989 259 262
9. J.H. Hong, C.S. Tsai, and J.T. Chang The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy Int J Radiat Oncol Biol Phys 41 1998 823 830
10. O. Micke, F.J. Prott, U. Schafer, S. Tangerding, R. Potter, and N. Willich The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer Anticancer Res 20 2000 5113 5115
11. K. Ohara, Y. Tanaka, H. Tsunoda, M. Nishida, S. Sugahara, and Y. Itai Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging Obstet Gynecol 100 2002 781 787
12. A. Gadducci, R. Tana, A. Fanucchi, and A.R. Genazzani Biochemical prognostic factors and risk of relapses in patients with cervical cancer Gynecol Oncol 107 2007 S23 S26
13. E. Pras, P.H. Willemse, and A.A. Canrinus Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment Int J Radiat Oncol Biol Phys 52 2002 23 32
14. M. Maiman, G. Feuer, R.G. Fruchter, N. Shaw, and J. Boyce Value of squamous cell carcinoma antigen levels in invasive cervical carcinoma Gynecol Oncol 34 1989 312 316
15. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol 19 2001 4054 4057
16. G.J. Rustin, M.E. van der Burg, and C.L. Griffin Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 376 2010 1155 1163